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Background: In India, there is an urgent need to enhance the
hematopoietic stem cell transplant (HSCT) facilities. It is also
important to be certain that these procedures can be carried
out within the existing infrastructure of hospitals with
requisite expertise. Although, there is a sudden rise in
numbers of transplant centres in last 2-3 years, there is still a
lack of dedicated HSCT units equipped with special air-
handling facilities and high efﬁciency air (HEPA) ﬁlter rooms.
It is important to ascertain the safety of performing allogenic
HSCT in single rooms without HEPA ﬁlters.
Aim: To evaluate short and long term outcomes of allogenic
HSCT performed in non-HEPA ﬁltered single rooms.
Patients and Methods: We analysed ﬁrst 123 consecutive
patients, who underwent an allogenic HSCT performed in
non-HEPA ﬁltered air-conditioned single rooms with barrier
nursing over 7 years from July 2005 to August 2012. The
preferred source of stem cells was GCSF mobilised peripheral
blood stem cells (PBSC). In small donors, where PBSC was
technically difﬁcult, bone marrow was harvested under
general anaesthesia. All patients received antibacterial,
antifungal and antiviral prophylaxis. At the onset of fever,
systemic antibiotics were started. Antifungal agents were
added if fever persisted for 3 days.
Results: We present our experience of performing 123
consecutive HLA matched sibling donor allogenic trans-
plantations. Source of stem cells was peripheral blood in 105
(85.4%), bonemarrow in 16 (13.0%) and combined in 1 (0.8%),
and one died during the period conditioning regimen was
administered before infusion of stem cells. The indications
were severe aplastic anemia (SAA) 58 (47.2%), CML 16 (13%),
AML 17 (13.8%), ALL 7 (5.7%), biphenotypic AL 3 (2.4%),
thalassemia/CDA 17 (13.8%) andmyelodysplastic syndrome 4
(3.2%), PRCA 1 (0.8%). The mean age was 23.8 years (range:2.2 e 52 years, SD: 12.5 years) with 28 (22.8%) females and
95 (77.2%) males. Mean CD34 cell dose was 5.35 x 106/kg
(range: 0.7 e 10.24, SD: 2.08). Median time to neutrophil
engraftment was 10 days (range 8 e 21 days). Two patients
with thalassemia major who received bone marrow as stem
cell source did not engraft and succumbed to fungal pneu-
monia. Fever occurred in 104 (85.6%) patients for a median of
6 days (range 2 e 10 days). Systemic antibiotics were used in
all thosewho had fever and antifungals in 48 (39%) cases. The
30 day mortality was 11 (8.9%) and 100 day mortality was 17
(13.8%). There were 26 (21.1%) fatalities in total, due to failure
to engraft 2, platelet refractoriness leading to intracranial
bleed 2, VOD 2, relapse 3, graft rejection 3, acute GvHD 3,
chronic GvHD 2, infections like disseminated TB 3 and
aspergillosis 6.
Conclusion: The result of this study highlights the fact that
allogenic BMT can be performed successfully with manage-
able toxicity in majority of cases under resource crunch
settings.369
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Background: Clostridium difﬁcile infection (CDI) is one of
the leading causes of hospital-acquired infections in recent
times. Hematopoietic stem cell transplantation (HSCT) con-
fers increased risk for CDI because of prolonged hospital stay,
immunosuppression, the need to use broad spectrum anti-
biotics and a complex interplay of preparative regimen and
graft versus host disease (GVHD)-induced gut mucosal
damage. Although there have been studies describing the
epidemiology and risk factors (RF) for CDI in HSCT recipients,
there are little data regarding recurrence rate of CDI and RF
associated with recurrence in this particular patient popu-
lation, especially given the ubiquity of traditional RF for CDI
in this population.
Aim: To evaluate the recurrence rate and RF associated with
recurrent CDI in allogeneic HSCT recipients.
Design and Methods: We conducted a retrospective, single
center study of 499 allogeneic HSCT recipients transplanted
between 2005 and 2012; of these, 61 (12%) developed CDI
within 6 months prior to transplant or 2 years after trans-
plant and were included in the analysis. Recurrent CDI was
deﬁned as recurrence after appropriate treatment of ﬁrst
episode which occurred in 20 (33%) of patients. Variables
including age, antibiotic use, proton pump inhibitor use,
presence of GVHD and other patient and transplant charac-
teristics were analyzed as potential RFs for recurrence.
Results: The 61 patients had a median age of 49 yrs (range 2-
73 yrs) and M:F ratio of 1.1. 74% received myeloablative
regimen and 26% received non-myeloablative regimen for
HSCTand acute GVHDwas seen in 59% of patients. Once-year
incidence of CDI recurrence in our study was 31% compared
tow20% recurrence in other series. Fine and Gray regression
analysis identiﬁed the number of antecedent antibiotics
other than those used to treat CDI as the only signiﬁcant RF
for recurrence (Hazard ratio (HR) 1.96, 95% Conﬁdence In-
terval (CI) 1.09-3.52, P ¼ 0.025). Most recurrences occurred
